1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,327 | 0,351 | 16:28 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SPRINT BIOSCIENCE Aktie jetzt für 0€ handeln | |||||
| Do | Sprint Bioscience AB: Sprint Bioscience announces agreement with Lilly TuneLab to accelerate drug development | 155 | GlobeNewswire (Europe) | Sprint Bioscience AB (publ) today announced that it has entered into an agreement with Lilly TuneLab, a collaborative AI-driven drug discovery platform created by Eli Lilly and Company (Lilly). By joining... ► Artikel lesen | |
| 13.05. | Sprint Bioscience AB Q1 Loss Widens | 1 | RTTNews | ||
| 16.04. | Sprint Bioscience AB: Sprint Bioscience completes strategic STK25 evaluation; continued focus on the primary indication | 220 | GlobeNewswire (Europe) | Sprint Bioscience AB (publ) today announces the conclusion of a targeted evaluation of the STK25 program, conducted in partnership with the Experimental Drug Development Centre (EDDC), Singapore's national... ► Artikel lesen | |
| 01.04. | Sprint Bioscience AB: Sprint Bioscience appoints Jenni Björnulfson as CFO | 180 | GlobeNewswire (Europe) | Sprint Bioscience AB (publ) today announces that Jenni Björnulfson has been appointed chief Financial Officer (CFO) of the company. With extensive and diverse experience in both life science and finance... ► Artikel lesen | |
| 01.04. | Sprint Bioscience AB: Positive results expand the NNMT program into Chronic Kidney Disease | 208 | GlobeNewswire (Europe) | Sprint Bioscience AB (publ) today announces positive results from its NNMT program from a proof-of-concept study demonstrating therapeutic potential in Chronic Kidney Disease (CKD). Based on these findings... ► Artikel lesen | |
| 17.03. | Sprint Bioscience AB: Sprint Bioscience reports positive results from the VRK1 program | 231 | GlobeNewswire (Europe) | Sprint Bioscience AB (publ) today announces positive results from a pre-clinical proof-of-concept (POC) study performed within the company's VRK1 program. The results show that VRK1 inhibition selectively... ► Artikel lesen | |
| 24.11.25 | Sprint Bioscience Announces Sale Of TREX1 Program to Gilead Sciences | 1.001 | AFX News | FOSTER CITY (dpa-AFX) - Sprint Bioscience AB (SPRINT.ST) announced the sale of its TREX1 cancer program to Gilead Sciences. The deal includes an upfront payment of $14 million, as well as potential... ► Artikel lesen |
7 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | 7,610 | 0,00 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 4,695 | -0,84 % | COSCIENS Biopharma Inc. Completes Share Capital Amendment | TORONTO, ONTARIO, July 03, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) ("COSCIENS" or the "Company"), today announced the previously announced consolidation (the "Consolidation")... ► Artikel lesen | |
| HALOZYME THERAPEUTICS | 71,60 | -0,64 % | Panik im Milliarden-Markt: Novo Nordisk und Halozyme Therapeutics mit Gegenwind - BioNxt Solutions vor Richtungsentscheidung | Im gigantischen Markt für Medikamente geht es um viele Milliarden. Umso erstaunlicher ist, dass in der Pharmaindustrie nicht nur der reine Wirkstoff entscheidet, sondern immer häufiger, wie Wirkstoffe... ► Artikel lesen | |
| ABCELLERA BIOLOGICS | 4,805 | +2,78 % | AbCellera-Aktie nach Rücksetzer mit +250% Potenzial? | Die AbCellera-Aktie hat nach ihrer starken Aufwärtsbewegung zuletzt eine gesunde Korrektur eingelegt und damit einen Teil der vorherigen Gewinne abgegeben. Nun richtet sich der Blick der Anleger erneut... ► Artikel lesen | |
| BIO-RAD LABORATORIES | 277,60 | -0,36 % | ROUNDUP/'WSJ': US-Investor Elliot steigt bei Sartorius-Großaktionär Bio-Rad ein | NEW YORK (dpa-AFX) - Der US-Investor Elliott hat laut einem Medienbericht eine beachtliche Beteiligung an dem Sartorius-Großaktionär Bio-Rad Laboratories aufgebaut. Der aktivistische Investor wolle... ► Artikel lesen | |
| GLOW LIFETECH | 0,017 | -15,00 % | Glow Lifetech Corp.: Glow Lifetech Advances National Expansion Strategy with Quebec Commercial Partnership | Toronto, Ontario--(Newsfile Corp. - July 13, 2026) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to announce it has entered into an exclusive Quebec... ► Artikel lesen | |
| AVID BIOSERVICES | - | - | Avid Bioservices Appoints Maria Ebro Andreasen as Chief People Officer to Fuel Continued Growth and Talent Strategy | Company expands team, university partnerships, and internship programs to build long-term biologics talent pipeline.TUSTIN, Calif., May 18, 2026 /PRNewswire/ -- Avid Bioservices, a leading... ► Artikel lesen | |
| BIOLINERX | 2,200 | -8,33 % | BioLineRx Ltd.; Hemispherian AS: BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model | Synergy was demonstrated in a combination arm of GLIX1 and the PARP inhibitor olaparib at low doses, with substantially better efficacy compared to the control arm and compared to each... ► Artikel lesen | |
| PARATEK PHARMACEUTICALS | - | - | Paratek Pharmaceuticals: $1.3 Billion Financing Supports Radius Health Combination To Build Specialty Pharma Platform | ||
| MINERVA NEUROSCIENCES | 3,638 | +2,48 % | Minerva Neurosciences, Inc: Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs | Distinguished panel of experts in psychiatry and neuroscience appointed to guide Phase 3 confirmatory trial of roluperidone and broader R&D strategyBURLINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| WHITEHAWK THERAPEUTICS | 3,400 | +4,29 % | Akari Therapeutics Plc: Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics | TAMPA, Fla. and LONDON, July 21, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing... ► Artikel lesen | |
| OVID THERAPEUTICS | 2,000 | -2,91 % | B.Riley reiterates Buy on Ovid Therapeutics stock, $5 target | ||
| COCRYSTAL | 0,820 | +1,86 % | Cocrystal Pharma, Inc.: Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer | BOTHELL, Wash., June 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a clinical-stage biotechnology company developing novel therapeutics to meet... ► Artikel lesen | |
| INNOVENT BIOLOGICS | 9,770 | -2,15 % | CMBI: Valuation Recovery in China's Innovative Drug Sector to Continue, Top Picks Include INNOVENT BIO | ||
| GEOVAX LABS | 0,783 | +7,08 % | EQS-News: GeoVax, Inc.: GeoVax Highlights Strategic Alignment of GEO-MVA With HHS/ASPR's Five-Year Medical Countermeasure Preparedness Strategy | EQS-News: GeoVax, Inc.
/ Key word(s): Financial
GeoVax Highlights Strategic Alignment of GEO-MVA With HHS/ASPR's Five-Year Medical Countermeasure Preparedness Strategy 21.07.2026... ► Artikel lesen |
SPRINT BIOSCIENCE AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -1,89 % bei einem Aktienkurs von 0,311 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SPRINT BIOSCIENCE AB finden Sie auf Wallstreet Online.